A Novel Orally Active Small Molecule Potently Induces G1 Arrest in Primary Myeloma Cells and Prevents Tumor Growth by Specific Inhibition of Cyclin-Dependent Kinase 4/6
Open accessPublished version of a preprint
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Cell cycle deregulation is central to the initiation and fatality of multiple myeloma, the second most common hematopoietic cancer, although impaired apoptosis plays a critical role in the accumulation of myeloma cells in the bone marrow. The mechanism for intermittent, unrestrained proliferation of myeloma cells is unknown, but mutually exclusive activation of cyclin-dependent kinase 4 (Cdk4)-cyclin D1 or Cdk6-cyclin D2 precedes proliferation of bone marrow myeloma cells in vivo. Here, we show that by specific inhibition of Cdk4/6, the orally active small-molecule PD 0332991 potently induces G(1) arrest in primary bone marrow myeloma cells ex vivo and prevents tumor growth in disseminated human myeloma xenografts. PD 0332991 inhibits Cdk4/6 proportional to the cycling status of the cells independent of cellular transformation and acts in concert with the physiologic Cdk4/6 inhibitor p18(INK4c). Inhibition of Cdk4/6 by PD 0332991 is not accompanied by induction of apoptosis. However, when used in combination with a second agent, such as dexamethasone, PD 0332991 markedly enhances the killing of myeloma cells by dexamethasone. PD 0332991, therefore, represents the first promising and specific inhibitor for therapeutic targeting of Cdk4/6 in multiple myeloma and possibly other B-cell cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Depending on the cell type and the transforming event, some Rb-positive cells undergo quiescence and others undergo senescence when treated with CDK4/6 inhibitors (Baughn et al., 2006; Choi et al., 2012; Kovatcheva et al., 2015; Michaud et al., 2010; Puyol et al., 2010).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Baughn et al., 2006
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115 · cited 1×
“of Cdk2 is inhibited by CKIs of the Cip/Kip family (7).”
BackgroundA Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632 · cited 1×
“(45), only 30% of multiple myeloma patients respond (44), and the”
BackgroundMeijer, L., Borgne, A., Mulner, O., Chong, J. P. J., Blow, J. J., Inagaki, N., Inagaki, M., Delcros, J., & Moulinoux, J. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.t01-2-00527.x · Cited by 1,352
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236 · cited 12×
“Phosphorylation of the retinoblastoma protein p105 (Rb) by Cdk4 or Cdk6 together with cyclin D in early G 1 and by Cdk2 in conjunction with cyclin E in late G 1 leads to the release of E2F transcription factors and S-phase entry (8).”
BackgroundMethodResultInfluentialSelf-citationThe Rb/E2F pathway: expanding roles and emerging paradigms
Harbour, J. W., & Dean, D. C. (2000) · Genes & Development · doi:10.1101/gad.813200 · Cited by 1,153 · cited 1×
“together with cyclin D in early G1 and by Cdk2 in conjunction with cyclin E in late G1 leads to the release of E2F transcription factors and S-phase entry (8).”
BackgroundMammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6
Malumbres, M., Sotillo, R., Santamarı́a, D., Galán, J., Cerezo, A., Ortega, S., Dubus, P., & Barbacid, M. (2004) · Cell · doi:10.1016/j.cell.2004.08.002 · Cited by 793 · cited 1×
“Cdk4 and Cdk6 are dispensable for development (40).”
BackgroundCharacterization of clonogenic multiple myeloma cells
Matsui, W., Huff, C. A., Wang, Q., Malehorn, M. T., Barber, J., Tanhehco, Y., Smith, B. D., Civin, C. I., & Jones, R. J. (2004) · Blood · doi:10.1182/blood-2003-09-3064 · Cited by 789 · cited 1×
“plasma cells, which are permanently withdrawn from the cell cycle (2, 3), multiple myeloma cells retain their self-renewing potential (4, 5).”
BackgroundGuan, K. L., Jenkins, C. W., Li, Y., Nichols, M. A., Wu, X., O'Keefe, C. L., Matera, A. G., & Xiong, Y. (1994) · Genes & Development · doi:10.1101/gad.8.24.2939 · Cited by 714 · cited 2×
“p18 inhibits Cdk4/6 mainly by forming a stable inactive binary complex, thereby precluding the activation of Cdk4/6 by D cyclins (9).”
BackgroundDevelopment of the Proteasome Inhibitor Velcade™ (Bortezomib)
Adams, J., & Kauffman, M. (2004) · Cancer Investigation · doi:10.1081/cnv-120030218 · Cited by 654 · cited 3×
“Although Bortezomib is widely used in the treatment of myeloma (45), only 30% of multiple myeloma patients respond (44), and the basis for Bortezomib resistance remains unknown.”
BackgroundHirai, H., Roussel, M. F., Kato, J.-Y., Ashmun, R. A., & Sherr, C. J. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.5.2672 · Cited by 646 · cited 1×
“Inhibition of Cdk6 by p18 (p18) of the INK4 family (9, 10) is required for G1 arrest and differentiation of antibody-secreting, end-stage plasma cells from antigen-activated B cells in vivo and in vitro”
Background
Cited by
Targeting apoptosis in cancer therapy
Carneiro, B. A., & El-Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,542
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Sicinski, P. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,858
Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
“Preclinical studies have demonstrated that PD 0332991 induces G1 arrest in primary bone marrow cells ex vivo and prevents tumor growth in disseminated human myeloma xenografts [30].”
BackgroundCyclin D as a therapeutic target in cancer
Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3090 · Cited by 1,370
“CDK4/CDK6 inhibitors may also lead to enhanced efficacy when used in combination with other therapies — for example, the proteasome inhibitor bortezomib or dexamethasone in multiple myelom”
BackgroundTreating cancer with selective CDK4/6 inhibitors
O'Leary, B., Finn, R. S., & Turner, N. C. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.26 · Cited by 1,137
Metadata
- Authors
- Baughn, L. B., Di Liberto, M., Wu, K., Toogood, P. L., Louie, T., Gottschalk, R., Niesvizky, R., Cho, H., Ely, S., Moore, M. A. S., & Chen-Kiang, S.
- Affiliations
- 1Pathology and Departments of
- Memorial Sloan Kettering Cancer Center (US)
- Pfizer (United States) (US)
- Cornell University (US)
- 2Medicine and
- Venue
- Cancer Research
- Published
- 2006-08-01
- Volume
- 66
- Issue
- 15
- Pages
- 7661-7667
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2125211913
- Cited by
- 225
- References
- 45
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 9 · 2023: 4 · 2022: 8 · 2021: 9 · 2020: 12 · 2019: 15 · 2018: 16 · 2017: 18 · 2016: 12 · 2015: 16 · 2014: 11 · 2013: 13 · 2012: 19
- FWCI
- 6.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR049436, R01 AR 49436)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Keywords
- multiple myeloma, palbociclib, G1 cell cycle arrest, oral small-molecule inhibitor, p18INK4c, dexamethasone combination therapy, tumor growth inhibition
- MeSH terms
- Animals, Dexamethasone, Humans, Multiple Myeloma, Piperazines, Pyridines, G1 Phase, Mice, SCID, Mice, Inbred NOD, Xenograft Model Antitumor Assays, Cell Growth Processes, Cyclin-Dependent Kinase Inhibitor p18, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Novel Orally Active Small Molecule Potently Induces G1 Arrest in Primary Myeloma Cells and Prevents Tumor Growth by Specific Inhibition of Cyclin-Dependent Kinase 4/6. https://app.cochat.ai/papers/10.1158/0008-5472.can-06-1098
- The paper
- Baughn, L. B., Di Liberto, M., Wu, K., Toogood, P. L., Louie, T., Gottschalk, R., Niesvizky, R., Cho, H., Ely, S., Moore, M. A. S., & Chen-Kiang, S. (2006). A Novel Orally Active Small Molecule Potently Induces G1 Arrest in Primary Myeloma Cells and Prevents Tumor Growth by Specific Inhibition of Cyclin-Dependent Kinase 4/6. Cancer Research. https://doi.org/10.1158/0008-5472.can-06-1098
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.